Early experience with Watson for oncology in Korean patients with colorectal cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Eui Joo | - |
dc.contributor.author | Woo, Hyun Sun | - |
dc.contributor.author | Cho, Jae Hee | - |
dc.contributor.author | Sym, Sun Jin | - |
dc.contributor.author | Baek, Jeong-Heum | - |
dc.contributor.author | Lee, Won-Suk | - |
dc.contributor.author | Kwon, Kwang An | - |
dc.contributor.author | Kim, Kyoung Oh | - |
dc.contributor.author | Chung, Jun-Won | - |
dc.contributor.author | Park, Dong Kyun | - |
dc.contributor.author | Kim, Yoon Jae | - |
dc.date.available | 2020-02-27T03:43:02Z | - |
dc.date.created | 2020-02-04 | - |
dc.date.issued | 2019-03-25 | - |
dc.identifier.issn | 1932-6203 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/1703 | - |
dc.description.abstract | Background Watson for oncology (WFO) is a cognitive computing system providing decision support. We evaluated the concordance rates between the treatment options determined by WFO and those determined by a multidisciplinary team (MDT). Methods We reviewed the medical charts of patients diagnosed with colorectal cancer who visited the MDT at a single tertiary medical center from November 2016 to April 2017. WFO classified the treatment options for specific patients into three categories: 'Recommended', 'For consideration', and 'Not recommended'. Concordance rates between the WFO- and MDT-determined chemotherapy options, and the factors that potentially influence the concordance rate, were analyzed. Results Sixty-nine patients with colorectal cancer met with the MDT from Nov. 2016 to Feb. 2017. The mean age of the patients was 62 years (range: 34-86 years), and more patients were male (47/69) than female. Of the 69 patients, 51 (73.9%) were diagnosed with colon cancer, of whom 46.4% received the same regimen recommendation from WFO ('Recommended') as they did from the MDT. After inclusion of the 'For consideration' category from WFO, the concordance rate increased to 87.0%. The concordance rate between MDT and NCCN guidelines was 97.1%, and that between the WFO and NCCN guidelines was 88.4%. The concordance rates between WFO and MDT were significantly lower in patients with stage II, IIIC, or IV disease (P<0.001), and the colorectal cancer stage was the only statistically significant factor discriminating between WFO and MDT. Conclusions The concordance rate between chemotherapy regimens for colorectal cancer determined by MDT versus WFO recommendations was 46.4%. After including the 'For consideration' category from WFO, the concordance rate increased to 88.4%. Further modification and improvement of the WFO prioritizing algorithm used to recommend treatment may increase the usefulness of WFO in the clinic. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | PUBLIC LIBRARY SCIENCE | - |
dc.relation.isPartOf | PLOS ONE | - |
dc.subject | SURGICAL ADJUVANT BREAST | - |
dc.subject | COLON-CANCER | - |
dc.subject | 1ST-LINE THERAPY | - |
dc.subject | FLUOROURACIL | - |
dc.subject | CHEMOTHERAPY | - |
dc.subject | BEVACIZUMAB | - |
dc.subject | LEUCOVORIN | - |
dc.subject | EFFICACY | - |
dc.subject | OXALIPLATIN | - |
dc.subject | TRIAL | - |
dc.title | Early experience with Watson for oncology in Korean patients with colorectal cancer | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000462157600012 | - |
dc.identifier.doi | 10.1371/journal.pone.0213640 | - |
dc.identifier.bibliographicCitation | PLOS ONE, v.14, no.3 | - |
dc.identifier.scopusid | 2-s2.0-85063492640 | - |
dc.citation.title | PLOS ONE | - |
dc.citation.volume | 14 | - |
dc.citation.number | 3 | - |
dc.contributor.affiliatedAuthor | Kim, Eui Joo | - |
dc.contributor.affiliatedAuthor | Woo, Hyun Sun | - |
dc.contributor.affiliatedAuthor | Cho, Jae Hee | - |
dc.contributor.affiliatedAuthor | Sym, Sun Jin | - |
dc.contributor.affiliatedAuthor | Baek, Jeong-Heum | - |
dc.contributor.affiliatedAuthor | Lee, Won-Suk | - |
dc.contributor.affiliatedAuthor | Kwon, Kwang An | - |
dc.contributor.affiliatedAuthor | Kim, Kyoung Oh | - |
dc.contributor.affiliatedAuthor | Chung, Jun-Won | - |
dc.contributor.affiliatedAuthor | Park, Dong Kyun | - |
dc.contributor.affiliatedAuthor | Kim, Yoon Jae | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | SURGICAL ADJUVANT BREAST | - |
dc.subject.keywordPlus | COLON-CANCER | - |
dc.subject.keywordPlus | 1ST-LINE THERAPY | - |
dc.subject.keywordPlus | FLUOROURACIL | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | BEVACIZUMAB | - |
dc.subject.keywordPlus | LEUCOVORIN | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | OXALIPLATIN | - |
dc.subject.keywordPlus | TRIAL | - |
dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
dc.relation.journalWebOfScienceCategory | Multidisciplinary Sciences | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.